2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 121

The Effectiveness of Tonsillectomy in Periodic Fever, Aphthous Ulcer, Pharyngitis, and Adenitis Syndrome in Pediatric Patients
Abstract Number: 122

Juvenile Arthritis in Minnesota: Geospatial Variability and Environmental Exposures in Juvenile Idiopathic Arthritis
Abstract Number: 123

Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review
Abstract Number: 124

JIA-Associated TMJ Arthritis, Idiopathic Condylar Resorption or Anterior Disc Displacement – a Care Provider Survey
Abstract Number: 125

Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic
Abstract Number: 126

Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture
Abstract Number: 127

What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency
Abstract Number: 128

Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions
Abstract Number: 129

Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)
Abstract Number: 130

Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Abstract Number: 131

Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative
Abstract Number: 132

Quality Improvement Lessons in a New Practice
Abstract Number: 133

An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients
Abstract Number: 134

Patient-Provider Communication in Pediatric Rheumatology
Abstract Number: 135

Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].